Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
25.58
+0.52 (2.06%)
At close: Sep 20, 2024, 3:54 PM
25.62
+0.05 (0.18%)
After-hours: Sep 20, 2024, 4:00 PM EDT
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $12.09M in the quarter ending May 31, 2024, a decrease of -60.58%. This brings the company's revenue in the last twelve months to $62.30M, up 2.25% year-over-year. In the fiscal year ending November 30, 2023, Nurix Therapeutics had annual revenue of $76.99M with 99.31% growth.
Revenue (ttm)
$62.30M
Revenue Growth
+2.25%
P/S Ratio
22.76
Revenue / Employee
$219,377
Employees
284
Market Cap
1.65B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 5.28B |
Teladoc Health | 2.61B |
Tilray Brands | 788.94M |
BioCryst Pharmaceuticals | 382.24M |
STAAR Surgical Company | 332.94M |
CareDx | 297.08M |
Harrow | 154.15M |
Bicycle Therapeutics | 39.57M |
NRIX News
- 14 days ago - Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit - GlobeNewsWire
- 16 days ago - Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data - Seeking Alpha
- 22 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case - Seeking Alpha
- 3 months ago - Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) - GlobeNewsWire
- 4 months ago - Nurix Therapeutics Appoints Paula G. O'Connor, M.D. - GlobeNewsWire
- 4 months ago - Nurix Therapeutics Announces Board Chair Transition - GlobeNewsWire